Scribe to Present Heart Therapy Data in Chicago
Scribe Therapeutics will share preclinical data on two cardiovascular candidates at the American Heart Association Scientific Sessions in November.
Updated on Nov. 4, 2026 in Biotech
Scribe Therapeutics, a clinical-stage biotechnology company listed on Nasdaq under the ticker SCTX, will present preclinical data on STX-1150 and STX-1200 at the American Heart Association Scientific Sessions in Chicago, Illinois, from November 6-9, 2026. The company's CEO will also take part in two sessions of the inaugural AHA Innovation Forum.
Why it matters
The presentations will show how two investigational therapies aim to lower cardiovascular risk markers through different genetic approaches. Readers in California, where the company announced the event from Alameda, can follow how a Bay Area biotech is positioning its cardiovascular pipeline ahead of the conference.
Preclinical studies in non-human primates showed LDL-C control lasting at least two years, based on company-reported data to be presented at the conference. Human results for STX-1150 remain pending from its ongoing Phase 1 trial in adults with elevated LDL-C.
The players
Scribe Therapeutics
A clinical-stage biotechnology company listed on Nasdaq under the ticker SCTX, co-founded by Nobel Prize winner Jennifer Doudna and with strategic collaborations with Sanofi and Eli Lilly.
American Heart Association
A national nonprofit organization focused on cardiovascular health that hosts the annual Scientific Sessions for researchers and clinicians.
The details
STX-1150 is an epigenetic silencing therapy designed to repress PCSK9 without permanently altering the underlying DNA sequence, and it is being evaluated in a first-in-human Phase 1 trial. STX-1200 is a CRISPR-based investigational gene editing prototype that edits the LPA gene in the liver to lower lipoprotein(a).
Timeline
November 6, 2026: AHA Innovation Forum sessions featuring CEO Benjamin Oakes begin.
November 7, 2026: Late-breaking presentations on STX-1150 and STX-1200 are scheduled.
November 6-9, 2026: American Heart Association Scientific Sessions take place in Chicago.
Big Picture
STX-1200 applies CRISPR gene editing to the LPA gene in the liver, extending a platform co-founded by Nobel laureate Jennifer Doudna into lipoprotein(a) reduction. Its approach sits alongside STX-1150's epigenetic method, which targets the same cardiovascular risk area without changing DNA sequence.
If the preclinical results hold in humans, the therapies could eventually offer new options for adults with elevated LDL-C or lipoprotein(a) who face higher cardiovascular risk. Any clinical use remains years away and depends on results from the ongoing Phase 1 trial.
The takeaway
Watch for the November 7 presentations to see how the preclinical data compares with the human results still pending from the Phase 1 trial. Readers tracking cardiovascular treatments should note that early-stage data is a step toward, not a substitute for, clinical proof.
What happens next
Late-breaking STX-1150 and STX-1200 presentations are scheduled for November 7, 2026, at the AHA Scientific Sessions in Chicago.
Further reading
For more on the field, see Biotech coverage across California.
Source note: This article includes information reported by The Manila times.
